ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 372 for:    Ankylosing Spondylitis

Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02762812
Recruitment Status : Completed
First Posted : May 5, 2016
Last Update Posted : February 23, 2018
Sponsor:
Information provided by (Responsible Party):
Biocad

Brief Summary:

BCD-055-2 is international multi-center comparative double-blind randomized clinical trial to evaluate efficacy and safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in patients with ankylosing spondylitis.

BCD-055 is biosimilar of infliximab (JSC "BIOCAD", Russia)


Condition or disease Intervention/treatment Phase
Ankylosing Spondylitis Biological: BCD-055 Biological: Remicade® Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 199 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: International Multi-center Comparative Double-blind Randomized Clinical Trial to Evaluate Efficacy and Safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in Patients With Ankylosing Spondylitis
Study Start Date : January 2016
Actual Primary Completion Date : May 2017
Actual Study Completion Date : July 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Infliximab

Arm Intervention/treatment
Experimental: BCD-055
Patients in this group will receive BCD-055 in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
Biological: BCD-055
Other Name: infliximab

Active Comparator: Remicade®
Patients in this group will receive Remicade® in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
Biological: Remicade®
Other Name: infliximab




Primary Outcome Measures :
  1. Ratio of patients with ASAS20 response after 30 weeks of therapy [ Time Frame: Week 30 ]
    Ratio of patients who developed a decrease in ankylosing spondylitis assessment score (ASAS) by 20% or more after 30 weeks of therapy with BCD-055.


Secondary Outcome Measures :
  1. Ratio of patients with ASAS20 response after 14 and 54 weeks of therapy [ Time Frame: Week 14, Week 54 ]
    Ratio of patients who developed a decrease in ankylosing spondylitis assessment score (ASAS) by 20% or more after 14 and 54 weeks of therapy with BCD-055.

  2. Ratio of patients with ASAS40 response after 14, 30 and 54 weeks of therapy [ Time Frame: Week 14, Week 30, Week 54 ]
    Ratio of patients who developed a decrease in ankylosing spondylitis assessment score (ASAS) by 40% or more after 14, 30 and 54 weeks of therapy with BCD-055.

  3. Mean change in BASDAI after 14, 30 and 54 weeks of therapy [ Time Frame: Week 14, Week 30, Week 54 ]
    Mean change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) after 14, 30 and 54 weeks of therapy

  4. Mean change in BASMI after 14, 30 and 54 weeks of therapy [ Time Frame: Week 14, Week 30, Week 54 ]
    Mean change in Bath Ankylosing Spondylitis Metrology Index (BASMI), after 14, 30 and 54 weeks of therapy

  5. Mean change in BASFI after 14, 30 and 54 weeks of therapy [ Time Frame: Week 14, Week 30, Week 54 ]
    Mean change in Bath Ankylosing Spondylitis Functional Index (BASFI) after 14, 30 and 54 weeks of therapy

  6. Mean change in MASES after 14, 30 and 54 weeks of therapy [ Time Frame: Week 14, Week 30, Week 54 ]
    Mean change in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) after 14, 30 and 54 weeks of therapy

  7. Mean SF-36 score at screening and after 14, 30 and 54 weeks of therapy [ Time Frame: Week 14, Week 30, Week 54 ]
    Mean score of quality of life as assessed by Short Form-36 (SF-36) at screening and after 14, 30 and 54 weeks of therapy

  8. Mean chest excursion at screening and after 14, 30 and 54 weeks of therapy [ Time Frame: Week 14, Week 30, Week 54 ]
    Mean chest excursion at screening and after 14, 30 and 54 weeks of therapy

  9. Mean quantity of abnormal peripheral joints after 14, 30 and 54 weeks of therapy [ Time Frame: Week 14, Week 30, Week 54 ]
    Mean quantity of abnormal peripheral joints after 14, 30 and 54 weeks of therapy

  10. Frequency of AE/SAE [ Time Frame: 54 weeks ]
    Frequency of AE/SAE

  11. Frequency of AE 3-4 grade CTCAE [ Time Frame: 54 weeks ]
    Frequency of AE 3-4 grade CTCAE



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Active ankylosing spondylitis according to modified criteria of New York classification (1984), that was diagnosed at least 3 months prior to screening.
  • Active disease according to BASDAI (score 4 or more) if nonsteroidal antiinflammatory drugs were used in the last 3 month prior to screening.
  • Mean backache intensity equals 4 points or more.

Exclusion Criteria:

  • Previous therapy of ankylosing spondylitis with monoclonal antibodies (including tumor necrosis factor)
  • Total spinal ankylosis
  • History of tuberculosis
  • Body mass more than 120 kg
  • Patient is taking corticosteroids for up to 4 weeks in a dose more than 10 mg (recalculated to prednisolone) before signing informed consent.
  • Prior use of disease-modifying antirheumatic drugs including methotrexate, sulfasalazin, chloroquine or hydroxychloroquine for up to 4 weeks before randomization.
  • Prior use of alkylating agents for up to 12 months prior to signing informed consent.
  • Intraarticular use of corticosteroids for up to 4 weeks before randomization.
  • Prior use of live or attenuated vaccines for up to 8 weeks before signing informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02762812


Locations
Russian Federation
North-Western State Medical University n.a. I.I.Mechnikov
St.Petersburg, Russian Federation
Sponsors and Collaborators
Biocad
Investigators
Study Chair: Roman Ivanov, PhD JCS BIOCAD

Responsible Party: Biocad
ClinicalTrials.gov Identifier: NCT02762812     History of Changes
Other Study ID Numbers: BCD-055-2
First Posted: May 5, 2016    Key Record Dates
Last Update Posted: February 23, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Spondylitis
Spondylitis, Ankylosing
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Joint Diseases
Arthritis
Infliximab
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents